	Des Atouts		Date
AbbVie	USD 133.9B	3.28B	2025-09
Acadia Pharmaceuticals	USD 1.33B	105.22M	2025-09
Akebia Therapeutics	USD 364.15M	18.56M	2025-09
ALKERMES	USD 2.33B	76.7M	2025-09
Alnylam Pharmaceuticals	USD 4.85B	285.64M	2025-09
Amarin	USD 659.81M	10.31M	2025-09
Amgen	USD 90.59B	445M	2025-12
Baxter International	USD 21.07B	21M	2025-09
Biogen	USD 29.44B	232M	2025-12
BioMarin Pharmaceutical	USD 7.61B	158.53M	2025-09
Bristol-Myers Squibb	USD 96.89B	2.21B	2025-09
Coherus Biosciences	USD 516.52M	77.05M	2025-09
Eli Lilly	USD 114.94B	14.01B	2025-09
Fujifilm	JPY 5.88T	349.29B	2025-12
Gilead Sciences	USD 58.53B	2.81B	2025-09
Ironwood Pharmaceuticals	USD 396.06M	53.12M	2025-09
Merck	USD 129.55B	12.02B	2025-09
Myriad Genetics	USD 728.1M	50.8M	2025-09
Pacira	USD 1.3B	239.68M	2025-09
Perrigo	USD 10.08B	10.1M	2025-09
Pfizer	USD 208.73B	2.64B	2025-09
PTC Therapeutics	USD 2.64B	9.54M	2025-09
Regeneron Pharmaceuticals	USD 40.56B	389.3M	2025-12
Sarepta Therapeutics	USD 3.49B	186.38M	2025-09
Teva Pharmaceutical Industries	USD 40.75B	892M	2025-12
Vertex Pharmaceuticals	USD 24.86B	825.6M	2025-09
Xencor	USD 868.81M	10.61M	2025-09
Zoetis	USD 15.16B	680M	2025-09

Coherus Biosciences Des Atouts - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Feb 2026.